Medicines that matter: Biohaven’s Nurtec™ drug development journey
In February 2020, Biohaven Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved Nurtec™ (Rimegepant) for the acute treatment of migraines in adults. In May 2021 the FDA also approved Nurtec™ for the prevention of migraine. Nurtec™ was approved in the European Union (EU) for both prevention and acute migraine treatment in April … Continued